RESEARCH TRIANGLE PARK, N.C., July 28, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a late-stage biopharmaceutical company, today announced that Vipin Garg, President and CEO, and Richard Eisenstadt, CFO, will present at the Canaccord Genuity Annual Growth Conference taking place in Boston August 9-11, 2011 at the InterContinental Hotel. Tranzyme's presentation is scheduled for Tuesday, August 9 at 10:00 A.M. ET in the San Francisco Room.
A live audio webcast of the presentation will be available in the "Investors" section of the Tranzyme Pharma website, www.tranzyme.com.
About Tranzyme Pharma
Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 20 percent of adults worldwide are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing an intravenous drug, ulimorelin, for patients in acute (hospital-based) settings, as well as an oral drug (TZP-102) for chronic conditions. Ulimorelin is currently in Phase 3 trials and TZP-102 is entering Phase 2b. Together these product candidates target a significant underserved market. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical need.
The Tranzyme, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9438